Pioneering Oncology and Rare Disease Therapies That Expand What Is Possible
Clinical Trials
We are dedicated to responsibly developing groundbreaking therapies for serious and life-threatening diseases.
Press Releases
- Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
- Kyntra Bio to Report First Quarter 2026 Financial Results
- Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
- Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
- Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination…
- Kyntra Bio to Participate in Upcoming Investor Conferences
- FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
- Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food…
Culture
Our culture is rooted in scientific rigor, operational excellence, and a shared commitment to patients. We foster an inclusive, collaborative environment where innovation thrives, accountability is expected, and every team member is empowered to make a meaningful impact.
Our Strategy
Discover how we have built a company that is intentional about changing lives.